HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

AKS-452 COVID-19 vaccine

CoV-2 Fc fusion protein subunit vaccine

Also Known As:

AKS-452; AKS-452 vaccine

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Complex Mixtures: 1906
- Biological Products
  - Vaccines: 124365
    - Subunit Vaccines: 1839
      - AKS-452 COVID-19 vaccine: 2
    - Viral Vaccines: 462
      - COVID-19 Vaccines: 7607
        AKS-452 COVID-19 vaccine: 2

Experts

1.	Alleva, David G: 2 articles (01/2022 - 10/2021)
2.	Delpero, Andrea R: 2 articles (01/2022 - 10/2021)
3.	Green, Freedom M: 2 articles (01/2022 - 10/2021)
4.	Haworth, Jeffrey R: 2 articles (01/2022 - 10/2021)
5.	Lancaster, Thomas M: 2 articles (01/2022 - 10/2021)
6.	Murikipudi, Sylaja: 2 articles (01/2022 - 10/2021)
7.	Nagre, Shashikant: 2 articles (01/2022 - 10/2021)
8.	Ragupathy, Ramya: 2 articles (01/2022 - 10/2021)
9.	Rao, Vidhya: 2 articles (01/2022 - 10/2021)
10.	Ronca, Shannon E: 2 articles (01/2022 - 10/2021)

Related Diseases

1.	Virus Diseases (Viral Diseases) 01/01/2022 - "No AEs ≥ 3, no SAEs attributable to AKS-452, and no SARS-CoV-2 viral infections occurred during the study. " 10/29/2021 - "AKS-452 is a biologically-engineered vaccine comprising an Fc fusion protein of the SARS-CoV-2 viral spike protein receptor binding domain antigen (Ag) and human IgG1 Fc (SP/RBD-Fc) in clinical development for the induction and augmentation of neutralizing IgG titers against SARS-CoV-2 viral infection to address the COVID-19 pandemic. "
2.	COVID-19 01/01/2022 - "Phase I interim results of a phase I/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452." 10/29/2021 - "Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452." 01/01/2022 - "To address the coronavirus disease 2019 (COVID-19) pandemic caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a recombinant subunit vaccine, AKS-452, is being developed comprising an Fc fusion protein of the SARS-CoV-2 viral spike protein receptor binding domain (SP/RBD) antigen and human IgG1 Fc emulsified in the water-in-oil adjuvant, Montanide™ ISA 720. " 10/29/2021 - "AKS-452 is a biologically-engineered vaccine comprising an Fc fusion protein of the SARS-CoV-2 viral spike protein receptor binding domain antigen (Ag) and human IgG1 Fc (SP/RBD-Fc) in clinical development for the induction and augmentation of neutralizing IgG titers against SARS-CoV-2 viral infection to address the COVID-19 pandemic. "
3.	Infections 10/29/2021 - "Furthermore, ISA 720-adjuvanted AKS-452 was immunogenic in rabbits and non-human primates (NHPs) and protected from infection and clinical symptoms with live SARS-CoV-2 virus in NHPs (USA-WA1/2020 viral strain) and the K18 human ACE2-trangenic (K18-huACE2-Tg) mouse (South African B.1.351 viral variant). " 10/29/2021 - "To further enhance immunogenicity, AKS-452 was evaluated in formulations containing a panel of adjuvants in which the water-in-oil adjuvant, Montanide™ ISA 720, enhanced neutralizing IgG titers by approximately 7-fold after one and two doses in mice, including the neutralization of live SARS-CoV-2 virus infection of VERO-E6 cells. " 01/01/2022 - "To address the coronavirus disease 2019 (COVID-19) pandemic caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a recombinant subunit vaccine, AKS-452, is being developed comprising an Fc fusion protein of the SARS-CoV-2 viral spike protein receptor binding domain (SP/RBD) antigen and human IgG1 Fc emulsified in the water-in-oil adjuvant, Montanide™ ISA 720. "

Related Drugs and Biologics

1.	Subunit Vaccines
2.	Immunoglobulin G (IgG)
3.	Proteins (Proteins, Gene)
4.	Antigens
5.	Vaccines
6.	K-18 conjugate (K18)